【摘要】 目的研究沙库巴曲缬沙坦钠与达格列净治疗糖尿病与心力衰竭的临床价值,并分析其对患者心功能的影响。方法选择我院2019年1月至2020年8月收治的74例糖尿病和心力衰竭患者作为本次研究病例,按照随机数字表法对患者分组,研究组和对照组各37例,对照组给予患者沙库巴曲缬沙坦钠治疗,研究组在对照组的基础上加用达格列净治疗,比较两组血糖水平、心室重塑指标、心功能指标、ADL评分,血压水平。结果治疗前两组心功能分级无统计学意义(P> 0.05),治疗后6个月,心功能分级结果显示,对照组治疗后,Ⅰ级8例,Ⅱ级15例,Ⅲ级9例,Ⅳ级5例,研究组治疗后,Ⅰ级16例,Ⅱ级15例,Ⅲ级5例,Ⅳ级1例,研究组治疗效果优于对照组。研究组血压水平、血糖水平优于对照组。ADL评分(73.25±11.01)高于对照组(68.51±9.11),研究组心功能指标NT-proBNP、LVEF、CO、心室重塑质量(LVMI、LVRI)优于对照组,体质量(71.94±6.04)低于对照组(75.16±6.10),有统计学意义(P <0.05)。结论糖尿病与心力衰竭患者应用达格列净与沙库巴曲缬沙坦钠联合治疗效果显著,可以改善患者心功能、控制血糖和血压水平。更多还原

【Abstract】 Objective To study the clinical value of Sacubitril Valsartan Sodium and Dapagliflozin in the treatment of diabetes and heart failure, and to analyze the effect of valsartan sodium on cardiac function. Methods A total of 74 patients with diabetes mellitus and heart failure admitted to our hospital from January 2019 to August 2020 were selected as the study cases, patients in the control group were treated with Sacubitril Valsartan Sodium and those in the study group were treated with Dapagliflozin on the basis control group. The blood glucose level, ventricular remodeling index, cardiac function index,ADL score and blood pressure were compared between the two groups. Results There was no significant difference between the two groups before treatment(P>0.05). Six months after treatment, there were 8 cases of grade Ⅰ, 15 cases of grade Ⅱ, 9 cases of grade Ⅲ and 5 cases of grade Ⅳ in the control group,and 16 cases of grade Ⅰ in the study group, there were 15 cases of grade Ⅱ, 5 cases of grade Ⅲ and 1 case of grade Ⅳ. The therapeutic effect of the study group was better than that of the control group. The blood pressure and blood sugar levels of the study group were better than those of the control group. The ADL score(73.25±11.01) was higher than that of the control group(68.51±9.11). The cardiac function indexes(NT-proBNP, LVEF, CO, LVMI and LVRI)of the study group were higher than that of the control group, and the body weight(71.94±6.04) was lower than that of the control group(75.16±6.10),which had statistical significance(P<0.05). Conclusion The combination therapy of Dapagliflozin and Sacubitril Valsartan Sodium can improve cardiac function, control blood sugar and blood pressure in patients with diabetes and heart failure. It is worthy of clinical application.更多还原